Pabst G, Lutz D, Molz K H, Dahmen W, Jaeger H
Arzneimittelforschung. 1986 Feb;36(2):256-60.
In a randomized three-way crossover study with twelve volunteers the bioavailability and main pharmacokinetic parameters of three different galenic formulations of nifedipine (hard gelatine capsule with pellets = preparation A, soft gelatine capsule with liquid nifedipine = preparation B, retard-tablet = preparation C) were determined. Plasma concentrations of nifedipine were measured by capillary gas-liquid chromatography up to 24 h after single dosing as well as up to 48 h after multiple doses of the drugs (steady state). Statistically significant differences between the preparations were found for AUC, Cmax, and Tmax. In all respects preparation A was intermediate to the other preparations. Plasma levels of 40 ng/ml or more were reached for most subjects within the first half hour after application of a single dose of preparation A and under steady state conditions plasma concentrations of 25 ng/ml or more could be upheld with this preparation for a longer time than with the reference retard tablet (preparation C). No accumulation of nifedipine in plasma occurred following multiple dosing.
在一项针对12名志愿者的随机三向交叉研究中,测定了三种不同剂型硝苯地平(含小丸的硬明胶胶囊=制剂A、含液体硝苯地平的软胶囊=制剂B、缓释片=制剂C)的生物利用度和主要药代动力学参数。单次给药后长达24小时以及多次给药(稳态)后长达48小时,通过毛细管气液色谱法测定血浆中硝苯地平的浓度。制剂之间在AUC、Cmax和Tmax方面存在统计学显著差异。在各方面,制剂A处于其他制剂之间。对于大多数受试者,单次服用制剂A后半小时内血浆水平可达40 ng/ml或更高,在稳态条件下,与参比缓释片(制剂C)相比,该制剂血浆浓度在25 ng/ml或更高水平可维持更长时间。多次给药后血浆中未出现硝苯地平蓄积。